Osanetant

Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones

Retrieved on: 
Monday, January 9, 2023
MA, Liver, Flash, Caregiver, Trauma, Aircraft pilot, Partnership, Intellectual property, Woman, IVMS, Acquisition, Adenocarcinoma, UCD School of Medicine, Prostate, University, UCD, Ammonia, Epilepsy, Food, Maple syrup urine disease, BSA, ACER, Blood, Education, Therapy, MSUD, Body surface area, Severity, FDA, VED, Post-traumatic stress disorder, VMS, Mouse, United States Department of Defense, Prostate cancer, OTC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Celiprolol, PCDC, PTSD, Patient, Diet, Emory University, Testosterone, Disorder, CPS, Pharmaceutical industry, Discover, Acer, Osanetant

NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.

Key Points: 
  • NEWTON, MA – January 09, 2023 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced a corporate update and provided anticipated key development milestones for 2023.
  • “Our commitment to patients is the cornerstone of our mission, and we are proud to have secured our first FDA approval.
  • We are eager to report the topline results from our ongoing Phase 2a trial of ACER-801 in moderate to severe VMS in post-menopausal women in Q1 of 2023.
  • These trial results will provide important insight into ACER-801’s therapeutic potential in induced VMS (iVMS).

Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate

Retrieved on: 
Thursday, January 5, 2023
Adenocarcinoma, Prostate cancer, ACER, Partnership, Acer, Testosterone, Therapy, MD, Prostate, Leuprorelin, Flash, University of Kansas Health System, ADT, Acquisition, Patient, University, Aircraft pilot, Oncology, Quality of life, Palliative care, VMS, Severity, Department of Medicine – University of Pamplona, Prostatectomy, Medical imaging, Osanetant

The POSH-MAP (Pilot of Osanetant for Severity of Hot Flashes in Men with Adenocarcinoma of the Prostate) and PORT-MAP (Pilot of Osanetant to Reduce Testosterone in Men with Adenocarcinoma of the Prostate) trials are being sponsored and conducted by The University of Kansas Cancer Center in partnership with Acer.

Key Points: 
  • The POSH-MAP (Pilot of Osanetant for Severity of Hot Flashes in Men with Adenocarcinoma of the Prostate) and PORT-MAP (Pilot of Osanetant to Reduce Testosterone in Men with Adenocarcinoma of the Prostate) trials are being sponsored and conducted by The University of Kansas Cancer Center in partnership with Acer.
  • Following the completion of treatment on day 28 participants will re-test hormone levels and report final patient outcome measures.
  • “However, the ability of NK3R antagonists to reduce testosterone to castrate levels in prostate cancer patients has not been evaluated to date.
  • ACER-801 is an investigational product candidate which has not been approved by FDA or any other regulatory authority.